Abstract
Lateral flow tests have played a key role in the response to the COVID-19 pandemic and are likely to be a major component of diagnostic strategies to combat future outbreaks of infectious disease. One challenge posed by widescale use of lateral flow tests in the community is the loss of sequence information to track virus evolution and epidemiology.
Beyond their primary diagnostic function, it has been demonstrated that recovery of viral RNA for genome sequencing purposes is possible, from positive lateral flow devices (LFDs).
To assess the robustness and broader applicability of this process, we assessed SARS-CoV-2 RNA recovery and sequencing from the four major LFDs in use in the UK.
Testing both cultured virus and residual clinical nasal swab samples demonstrated that sequencing from LFD eluates is possible, at clinically relevant titres, within a reasonable processing time frame post-use, and gave sequences concordant with routine methods, but results varied across the four devices used.
This highlights the requirement for refinement of existing LFDs or of second–generation LFD design, where sequencing is an intended output from positive LFDs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by WHO grant 2023/1385507.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of anonymised stored clinical samples for method evaluation was deemed to not require review by the UKHSA research ethics group
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.